Dexcom Inc (NASDAQ: DXCM), a provider of real-time continuous glucose monitoring (rtCGM) for diabetes patients, declared on Tuesday that it Dexcom G6 CGM System will be available to eligible people of all ages with type 1 and type 2 diabetes in Canadian province Manitoba.
Coverage for rtCGM will be expanded to include all eligible patients with type 1 or type 2 diabetes in Manitoba, which is currently the only province in Canada that does not require an application for preapproval of coverage.
The company said that this positive step ensures that Manitobans are able to improve their self-management of diabetes at home. This is expected to preserve vital health system capacity by reducing the risk of severe hypoglycemia which often results in patients requiring emergency care.
According to Dexcom, use of its rtCGM is proven to improve glycemic control and can reduce the risk of costly long-term diabetes-related complications. The system includes a small, wearable sensor and transmitter to continuously measure and send glucose levels wirelessly to a smart device or receiver, giving patients real-time glucose data without the need to scan or prick their finger routinely. Dexcom G6 has customisable and predictive alerts and an urgent low alarm to help avoid potentially dangerous hypoglycemic events. The Dexcom G6 app also allows patients to share their glucose information with up to ten followers.
Abbott receives CE Mark for Volt Pulsed Field Ablation System to treat atrial fibrillation
Vast Therapeutics' ALX1 drug candidate granted QIDP designation by US FDA
Qlife secures UK approval to initiate clinical trial for Egoo Phe System
Healthcare Holding Schweiz AG acquires Effectum CH-Rep AG to expand services
Femasys receives CE mark approval for FemBloc delivery system in Europe
Avance Biosciences registers with CLIA program
Abbott announces quarterly common dividend
Aiforia secures IVDR certification for expanded AI-powered cancer diagnostics in Europe
Limaca Medical launches Precision-GI endoscopic automated motorised EUS biopsy device in US
Owens & Minor launches ByramConnect digital health platform for diabetes management
Acrivon Therapeutics receives FDA Breakthrough Device designation for ACR-368 OncoSignature assay
BrainCool secures market approval for BrainCool System in Malaysia
Bioretec Ltd secures CE mark approval for RemeOs Trauma Screw portfolio
Biohit launches FAEX Sample System for stool sample collection